HKU Scholars Hub: Browsing DSpace

Browsing by Author Sangro, B

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 9 of 9

	Title	Author(s)	Issue Date
	Assessment of Inflammation Biomarkers in Relation to Clinical Outcomes in Nivolumab-Treated Patients With Advanced Hepatocellular Carcinoma in CheckMate 040 Proceeding/Conference:Journal of Hepatology	Sangro, B Melero, I Wadhawan, S Finn, R Abou-Alfa, GK Cheng, AL Yau, TCC Furuse, J Park, JW Boyd, Z Tang, HT Shen, Y Tschaika, M Neely, J El-Khoueiry, A	2019
	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial Journal:JAMA Oncology	Yau, TCC Kang, YK Kim, TY El-Khoueiry, AB Santoro, A Sangro, B Melero, I Kudo, M Hou, MM Matilla, A Tovoli, F Knox, JJ He, AR El-Rayes, BF Acosta-Rivera, M Lim, HY Neely, J Shen, Y Wisniewski, T Anderson, J Hsu, C	2020
	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Journal:Lancet	El-Khoueiry, AB Sangro, B Yau, TCC Crocenzi, TS Kudo, M Hsu, C Kim, TY Choo, SP Trojan, J Welling, TH Meyer, T Kang, YK Yeo, W Chopra, A Anderson, J Dela Cruz, C Lang, L Neely, J Tang, H Dastani, HB Melero, I	2017
	Phase 1/2 Safety and Antitumor Activity of Nivolumab in Patients With Advanced Hepatocellular Carcinoma: Interim Analysis of the CheckMate 040 Dose-Escalation Study Proceeding/Conference:Liver Cancer	El-Khoueiry, AB Sangro, B Yau, TCC Crocenzi, TS Welling, TH, III Yeo, W Chopra, A Anderson, J dela Cruz, C Lang, L Neely, J Melero, I	2016
	Posttransplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working group report from the ILTS Transplant Oncology Consensus Conference Journal:Transplantation	Berenguer, M Burra, P Ghobrial, M Hibi, T Metselaar, H Sapisochin, G Bhoori, S Man, K Mas, V Ohira, M Sangro, B van der Laan, LJW	2020
	Safety and Antitumor Activity of Nivolumab (Nivo) in Patients (pts) with Advanced Hepatocellular Carcinoma (HCC): Interim Analysis of Dose-Expansion Cohorts from the Phase 1/2 CheckMate-040 Study Proceeding/Conference:Liver Cancer	Sangro, B Melero, I Yau, TCC Hsu, C Kudo, M Crocenzi, TS Kim, TY Choo, SP Trojan, J Meyer, T Kang, YK Anderson, J dela Cruz, C Lang, L Neely, J El-Khoueiry, AB	2016
	Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I/II study Journal:Journal of Clinical Oncology	Kelley, RK Sangro, B Harris, W Ikeda, M Okusaka, T Kang, YK Qin, S Tai, DWM Lim, HY Yau, T Yong, WP Cheng, AL Gasbarrini, A Damian, S Bruix, J Borad, M Bendell, J Kim, TY Standifer, N He, P Makowsky, M Negro, A Kudo, M Abou-Alfa, GK	2021
	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma Journal:Journal for ImmunoTherapy of Cancer	Greten, TF Abou-Alfa, GK Cheng, AL Duffy, AG El-Khoueiry, AB Finn, RS Galle, PR Goyal, L He, AR Kaseb, AO Kelley, RK Lencioni, R Lujambio, A Mabry Hrones, D Pinato, DJ Sangro, B Troisi, RI Wilson Woods, A Yau, T Zhu, AX Melero, I	2021
	Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90 Journal:Oncology	Lau, WY Sangro, B Chen, PJ Poon, RTP	2013

Showing results 1 to 9 of 9